CClinicalTrials.gg
Status unknownNCT03045042BIOPOMPEUpdated Mar 20, 2017

Search for Serum/Plasma Biomarkers in Pompe's Disease

An observational study in Late Onset Pompe Disease and Pompe Disease, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Status unknown at 1 site in Spain. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational

The sponsor has not verified this record recently (last verified Jan 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
2 Years and older
Sex
All
01

Study summary

This study aims to analyze serum and plasma samples from patients with late onset Pompe disease treated and not treated with enzyme replacement therapy (ERT) to identify microRNA that could be specific of the disease. The investigators will correlate the concentration of these microRNA with several muscle function tests and quantitative muscle MRI to know whether they are good biomarkers of progression.

02

Conditions studied

  • Late Onset Pompe Disease
  • Pompe Disease

Keywords

  • Pompe
  • microRNA
  • biomarker
  • muscle MRI
  • glycogenosis
03

In context

Glycogen Storage Disease Type II

151 studies on the registry are indexed under Glycogen Storage Disease Type II; 30 are open to participants now.

This study's planned enrollment of 35 is below the median of 50 across 62 observational studies indexed under Glycogen Storage Disease Type II.

Browse Glycogen Storage Disease Type II studies →

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 335 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Late onset Pompe patiens

Inclusion criteria

  • Genetic confirmation of Pompe disease

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Treated patients

    Patients with late onset Pompe disease treated with the enzyme replacement therapy

    Drug: Enzyme Replacement Agent

  • Non treated patients

    Patients with late onset Pompe disease non treated with the enzyme replacement therapy

Interventions

  • DrugEnzyme Replacement Agent

    Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients

    Also known as: Myozyme

06

What researchers measure

Primary outcomes

  1. MicroRNA in serum samples

    Investigators are going to study microRNA following a microarray analysis of serum samples from patients treated and non treated

    Time frame: Baseline

Secondary outcomes

  1. Muscle function test

    6 minutes walking test (6MWT), time to climb 4 steps, time to descend 4 steps, Activlim, time to walk 10 meter, Medical Research Council scale (MRC), myometry

    Time frame: Baseline and one year

  2. Whole body muscle MRI

    2 point dixon studies of thigh muscles

    Time frame: Baseline a and one year

  3. Changes in microRNA concentration

    Investigators will analyze concentration of microRNA after one year follow up in every single patients

    Time frame: One year period

07

Study locations

1 site
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03045042
Lead sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
Genzyme, a Sanofi Company
Responsible party
Sponsor
First posted
Feb 7, 2017
Start date
Apr 2017 (estimated)
Primary completion
Jan 2018 (estimated)
Completion
Jan 2019 (estimated)
Last update
Mar 20, 2017

Study contacts

Eduard Gallardo, PhD
Contact
egallardo@santpau.cat
9355657682
Jordi Díaz Manera, MD PhD
Contact
jdiazm@santpau.cat
935565986

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion